Skip to main content
  • Bookmarks
  • Register
  • Login

NIH OIR/OTT Logo

Main Menu

  • Partnerships

    Partnerships

    These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

    • Overview
    • Opportunities
    • Featured Technologies
    • Collaboration / CRADAs
    • Licensing Process
    • Forms / Model Agreements
    • Startups
    • Non-Profits
    • License Materials
    • Licensing FAQs
    • Business Opportunities
    • Product Showcase
    • Product Pipeline
    • Federal Register Notices

    The NIH cannot commercialize its discoveries even with its considerable size and resources — it relies instead upon partners. Typically, a royalty-bearing exclusive license agreement with the right to sublicense is given to a company from NIH to use patents, materials, or other assets to bring a therapeutic or vaccine product concept to market.

  • Royalties

    Royalties

    Information for inventors and licensees on the administration of royalties.

    • Information for NIH Inventors
    • Information for Licensees
    • License Notices / Reports
    • Royalty Coordinators
    • NIH Payment Center
    • CDC Payment Center

    Each year, hundreds of new inventions are made at NIH and CDC laboratories. Nine NIH Institutes or Centers (ICs) transfer NIH and CDC inventions through licenses to the private sector for further research and development and eventual commercialization.

  • Reports

    Reports

    These links provide access to reports tracking the success of NIH licensed products.

    • Annual Reports
    • Tech Transfer Statistics
    • Tech Transfer Metrics
    • Commercial Outcomes
    • HHS License-Based Vaccines & Therapeutics
    • Public Health & Economic Impact Study
    • Stories of Discovery
    • Chen Lecture Videos
    • NIH Patents and Active Patent Commercialization Licenses
    • Media Room
    • Tech Transfer Newsletters
    • NIH Patents and Patent Applications

    The NIH, CDC and FDA Intramural Research Programs are exceptionally innovative as exemplified by the many products currently on the market that benefit the public every day. Reports are generated from the commonly tracked metrics related to these products.

  • Resources

    Resources

    These links provide resources to those interested in the technology transfer activities at NIH.

    • Forms and Model Agreements
    • License Notices / Reports
    • Video Library
    • Inventor Resources
    • Presentations & Articles
    • FAQs
    • RSS Feeds
    • Inventor Showcase

    Past videos, lectures, presentations, and articles related to technology transfer at NIH are kept and made available to the public. These topics range from general technology transfer information to processes specific to NIH.

  • Policy & Regulations

    Policies & Regulations

    These links provide access to the policies and regulations surrounding partnering or collaborating with NIH.

    • Freedom of Information Act (FOIA)
    • PHS Technology Transfer Policy
    • Policies & Reports
    • Useful Links

    If a company would like to acquire rights to use or commercialize either an unpatented material, or a patented or patent-pending invention, a license is required. There are numerous policies and regulations surrounding the transfer or a technology from the NIH to a company or organization.

  • About

    About Us

    These links provide information about the Office of Technology Transfer.

    • Contact Us
    • Staff Directory
    • Management
    • FAQs
    • HHS Tech Transfer Offices & Contacts
    • Careers in Tech Transfer
    • Location & Directions
    • Feedback

    The NIH Office of Technology Transfer (OTT) plays a strategic role by supporting the patenting and licensing efforts of our NIH ICs. OTT protects, monitors, markets and manages the wide range of NIH discoveries, inventions, and other intellectual property as mandated by the Federal Technology Transfer Act and related legislation.

Breadcrumb

  1. Home
  2. Taxonomy
  3. Term
  4. NCI

RNA Nanoparticles and Methods of Use

  • Read more about RNA Nanoparticles and Methods of Use
US Application 61/187,495
Filed on 2009-06-16

New Processes For Preparation Of Dendrimer-Based Bifunctional Diethylenetriaminepentaacetic Acid And DOTA Gd(III) MR Contrast Agent Derivatives

  • Read more about New Processes For Preparation Of Dendrimer-Based Bifunctional Diethylenetriaminepentaacetic Acid And DOTA Gd(III) MR Contrast Agent Derivatives
US Application 61/180,327
Filed on 2009-05-21

TREM-like Transcript-1 Protects Against Inflammation-associated Hemorrhage By Facilitating Platelet Aggregation In Mice And Humans

  • Read more about TREM-like Transcript-1 Protects Against Inflammation-associated Hemorrhage By Facilitating Platelet Aggregation In Mice And Humans
US Application 61/177,242
Filed on 2009-05-11

A 50-gene Predictor Of Chemoresistance

  • Read more about A 50-gene Predictor Of Chemoresistance
US Application 61/178,392
Filed on 2009-05-14

Akt-Ser473 Phosphorylation And Taxane-Based Chemotherapy

  • Read more about Akt-Ser473 Phosphorylation And Taxane-Based Chemotherapy
US Application 61/180,558
Filed on 2009-05-22

Prevention Of Tumor Recurrence Through Inhibition Of Fibrosis, Integrin Signaling, Src And ERK Activation And Actin Stress Fiber Formation.

  • Read more about Prevention Of Tumor Recurrence Through Inhibition Of Fibrosis, Integrin Signaling, Src And ERK Activation And Actin Stress Fiber Formation.
US Application 61/179,641
Filed on 2009-05-19

Development Of Peptide Mimetic Ligands Of Polo-like Kinase L Polo Box Domain

  • Read more about Development Of Peptide Mimetic Ligands Of Polo-like Kinase L Polo Box Domain
US Application 61/178,593
Filed on 2009-05-15

Combination Immunotherapy Compositions And Methods

  • Read more about Combination Immunotherapy Compositions And Methods
US Application 61/170,530
Filed on 2009-04-17

The Natural Product Schweinfurthin A And Synthetic Schweinfurthin Analogs Specifically Inhibit NF1-null Cells And May Be Useful As A Therapy For Neurofibromatosis Type 1.

  • Read more about The Natural Product Schweinfurthin A And Synthetic Schweinfurthin Analogs Specifically Inhibit NF1-null Cells And May Be Useful As A Therapy For Neurofibromatosis Type 1.
US Application 61/174,338
Filed on 2009-04-30

Inhibitors Of FKBP52-Mediated Regulation Of Androgen Receptor Function

  • Read more about Inhibitors Of FKBP52-Mediated Regulation Of Androgen Receptor Function
US Application 61/242,541
Filed on 2009-09-15

Pagination

  • First page « First
  • Previous page ‹‹
  • …
  • Page 121
  • Page 122
  • Page 123
  • Page 124
  • Page 125
  • Page 126
  • Page 127
  • Page 128
  • Page 129
  • …
  • Next page ››
  • Last page Last »
Subscribe to NCI
NIH White Technology Transfer Logo

Return to Top

  • About
  • Privacy Notice
  • Accessibility
  • Web Policies & Notices
  • Open Data
  •  
  • For NIH Staff Only
  • HHS
  • NIH
  • HHS Vulnerability Disclosure
  • Connect
  • Twitter
  • LinkedIn
  • Contact
  • Feedback

Office of Technology Transfer, Office of Intramural Research, National Institutes of Health